The Flavagline Compound 1-(2-(dimethylamino)acetyl)-Rocaglaol Induces Apoptosis in K562 Cells by Regulating the PI3K/Akt/mTOR, JAK2/STAT3, and MAPK Pathways

Abstract

Purpose Chronic myelogenous leukemia (CML) is a hematological malignancy with increased proliferation of cells of the myeloid series. This can disrupt normal hematopoiesis. The 1-(2-(dimethylamino)acetyl)-rocaglaol (MQ-16) is a new synthetic flavagline compound that showed promising activity in chronic myeloid leukemia K562 cells. This study aims to analyze the underlying mechanisms of MQ-16 against CML. Methods Growth, cell cycle progression, and apoptosis were assessed in K562 cells following MQ-16 exposure by MTT assay and flow cytometry. The effect of MQ-16 on DNA strands between nucleosomes was examined by 1% agarose gel electrophoresis. PI3K/Akt/mTOR, JAK2/STAT3, and mitogen-activated protein kinase (MAPK) pathway-related proteins were detected in MQ-16–treated K562 cells by Western blot. Results MQ-16 significantly inhibited the proliferation of K562 cells and arrested the cell cycle at the G2/M phase in a time- and concentration-dependent manner. MQ-16 induced mitochondria-dependent apoptosis by downregulating the anti-apoptotic proteins Bcl-2 and Bcl-xL and induced time- and concentration-dependent DNA fragmentation. In addition, MQ-16 affected the expression of PI3K/Akt/mTOR, JAK2/STAT3, and MAPK pathway-related proteins. Conclusion In summary, MQ-16 appears to be a promising chemotherapeutic drug for treating CML.

LILRB4 knockdown inhibits aortic dissection development by regulating pyroptosis and the JAK2/STAT3 signaling pathway

“…JAK2/STAT3 is a classical pathway responsible for the transcriptional activation and signal transduction of STAT 59 . Upon activation, the JAK/receptor complex facilitates the phosphorylation of STAT proteins, which then translocate to the nucleus and regulate the expression of downstream target genes 60 , 61 . In AD-induced acute lung injury, IL-22 inhibits Ang II-mediated pulmonary microvascular endothelial cell apoptosis and downregulates STAT3 expression and intranuclear delivery.…”

Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis

“…The MEK inhibitor, on the other hand, enhances growth inhibition and cell death in Calu-6 lung cancer cells treated with ATO ( 56 ). JNK and p38 will be activated while ERK is suppressed in order to cause apoptosis in cancer cells, as evidenced by the effects of dominant-interfering or constitutively active versions of particular JNK-p38 and ERK signaling pathway components ( 57 ). Lee et al ( 58 ) reported that As 4 S 4 could decrease the expression levels of specific proteins, such as Bcl-2 and p-ERK in the KRAS mutant cell lines A549 and H460 and exert an antiangiogenic effect, which led to the inhibition of tumor cell growth, proliferation, invasion, and metastasis.…”